Dren Bio
Clinical-stage biotech developing first-in-class antibody therapies for cancer and autoimmune disease
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Dren Bio is a clinical-stage biotechnology company in San Carlos, California, developing first-in-class antibody therapeutics for cancer and autoimmune diseases. Its lead program, dibotatug (DR-01), is a CD94-targeting antibody for rare blood cancers and other hematologic and autoimmune diseases. In October 2026 it announced an oversubscribed $350 million private financing co-led by Juvia Group and Lightspeed Venture Partners to fund late-stage development, regulatory submission and commercial launch of dibotatug and to advance its broader pipeline.
- Website
- drenbio.com
- Added via
- web
- Ownership
- unclaimed